1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Hypoglycemia - Pipeline Review, H1 2016

Hypoglycemia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 75 pages

Hypoglycemia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Hypoglycemia - Pipeline Review, H1 2016’, provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


Scope

- The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
- The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects
- The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hypoglycemia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hypoglycemia Overview 7
Therapeutics Development 8
Pipeline Products for Hypoglycemia - Overview 8
Hypoglycemia - Therapeutics under Development by Companies 9
Hypoglycemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Unknown Stage Products 13
Hypoglycemia - Products under Development by Companies 14
Hypoglycemia - Companies Involved in Therapeutics Development 15
Biodel Inc. 15
Eiger BioPharmaceuticals, Inc. 16
Eli Lilly and Company 17
Heptares Therapeutics Limited 18
Novartis AG 19
Sanofi 20
SkyePharma Plc 21
Therakind Limited 22
USV Limited 23
XERIS Pharmaceuticals, Inc. 24
XOMA Corporation 25
Zealand Pharma A/S 26
Hypoglycemia - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
AMG-5041 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Biologic for Hypoglycemia - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Drug for Hypoglycemia - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
exendin-(9-39) - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
glucagon - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
glucagon - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
glucagon - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
glucagon - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
LY-3143753 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
LY-3185643 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
pasireotide - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
SAR-438544 - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
terbutaline sulphate MR - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
XOMA-129 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
XOMA-358 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
ZP-4207 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Hypoglycemia - Recent Pipeline Updates 56
Hypoglycemia - Dormant Projects 64
Hypoglycemia - Discontinued Products 65
Hypoglycemia - Product Development Milestones 66
Featured News and Press Releases 66
Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes 66
Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism 66
Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia 67
Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand's stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia 67
Jun 26, 2015: Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy 68
Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia 69
May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207 69
Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial 70
Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting 72
Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015 72
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables
Number of Products under Development for Hypoglycemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Comparative Analysis by Unknown Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Hypoglycemia - Pipeline by Biodel Inc., H1 2016 15
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2016 16
Hypoglycemia - Pipeline by Eli Lilly and Company, H1 2016 17
Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H1 2016 18
Hypoglycemia - Pipeline by Novartis AG, H1 2016 19
Hypoglycemia - Pipeline by Sanofi, H1 2016 20
Hypoglycemia - Pipeline by SkyePharma Plc, H1 2016 21
Hypoglycemia - Pipeline by Therakind Limited, H1 2016 22
Hypoglycemia - Pipeline by USV Limited, H1 2016 23
Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016 24
Hypoglycemia - Pipeline by XOMA Corporation, H1 2016 25
Hypoglycemia - Pipeline by Zealand Pharma A/S, H1 2016 26
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Stage and Target, H1 2016 29
Number of Products by Stage and Mechanism of Action, H1 2016 31
Number of Products by Stage and Route of Administration, H1 2016 33
Number of Products by Stage and Molecule Type, H1 2016 35
Hypoglycemia Therapeutics - Recent Pipeline Updates, H1 2016 56
Hypoglycemia - Dormant Projects, H1 2016 64
Hypoglycemia - Discontinued Products, H1 2016 65

List of Figures
Number of Products under Development for Hypoglycemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 27
Number of Products by Targets, H1 2016 28
Number of Products by Stage and Targets, H1 2016 28
Number of Products by Mechanism of Actions, H1 2016 30
Number of Products by Stage and Mechanism of Actions, H1 2016 30
Number of Products by Routes of Administration, H1 2016 32
Number of Products by Stage and Routes of Administration, H1 2016 32
Number of Products by Molecule Types, H1 2016 34
Number of Products by Stage and Molecule Types, H1 2016 34

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N Sulphoglucosamine Sulphohydrolase ...

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.